BridgeBio PharmaBBIO
BBIO
About: BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Employees: 730
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
489% more call options, than puts
Call options by funds: $472M | Put options by funds: $80.1M
143% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 30
53% more repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 78
32% more capital invested
Capital invested by funds: $4.85B [Q4 2024] → $6.41B (+$1.56B) [Q1 2025]
20% more funds holding in top 10
Funds holding in top 10: 15 [Q4 2024] → 18 (+3) [Q1 2025]
15% more funds holding
Funds holding: 262 [Q4 2024] → 301 (+39) [Q1 2025]
3.88% more ownership
Funds ownership: 93.48% [Q4 2024] → 97.36% (+3.88%) [Q1 2025]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$50
26%
upside
Avg. target
$58
45%
upside
High target
$72
81%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju | 41%upside $56 | Buy Maintained | 9 Jun 2025 |
Scotiabank Greg Harrison | 38%upside $55 | Sector Outperform Maintained | 30 Apr 2025 |
Piper Sandler Biren Amin | 58%upside $63 | Overweight Maintained | 30 Apr 2025 |
UBS Eliana Merle | 81%upside $72 | Buy Maintained | 30 Apr 2025 |
Redburn Atlantic Joshua Smith | 26%upside $50 | Buy Initiated | 31 Mar 2025 |
Financial journalist opinion
Based on 4 articles about BBIO published over the past 30 days
Positive
Seeking Alpha
1 week ago
BridgeBio: New Data Bolsters The Bull Case
BridgeBio's Attruby launch crushed expectations, with Q1 revenue triple analyst estimates, driven by higher-than-expected conversion rates and minimal free trial usage. Competitive threats from Amvuttra appear overstated, as Attruby script declines were minor and BridgeBio management remains confident in market positioning and pricing. My updated model projects 2025 revenues of $728 million, far above consensus, and sees potential for nearly $1 billion in 2026 from existing patients alone.
Neutral
GlobeNewsWire
1 week ago
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, FL on Monday, June 9 at 8:40 am ET.
Neutral
GlobeNewsWire
3 weeks ago
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
- In a post-hoc analysis of ATTRibute-CM, acoramidis reduced the annual frequency of CVH due to AF/AFL by 43% compared to placebo and reduced the incidence of new-onset AF/AFL by 17% in the subgroup with no prior history of AF compared to placebo
Neutral
GlobeNewsWire
3 weeks ago
Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
- For each 5-mg/dL increase in serum TTR level within 28 days of starting treatment, the relative risk reduction of mortality was up to 31.6% through Month 30, confirming the hypothesis that ever better levels of stabilization achieved by treatment with acoramidis, a near-complete (≥90%) TTR stabilizer, lead to ever better clinical outcomes
Neutral
GlobeNewsWire
1 month ago
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on May 9, 2025, the compensation committee of BridgeBio's board of directors approved equity grants to 36 new employees in restricted stock units for an aggregate of 101,974 shares of the Company's common stock.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 63.9% in BridgeBio Pharma (BBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
GlobeNewsWire
1 month ago
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
- ATTRibute-CM, BridgeBio's Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients (59.1% risk reduction) , establishing the mechanistic hypothesis that stabilizing TTR may delay or prevent ATTRv-CM
Neutral
GlobeNewsWire
1 month ago
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC
PALO ALTO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire abstract and two moderated ePosters on the clinical outcomes and quality of life measures provided by acoramidis in variant transthyretin amyloid cardiomyopathy (ATTR-CM) and one moderated ePoster on a post-hoc analysis of the lower incidence rate of atrial fibrillation-related events in patients with ATTR-CM, all from the ATTRibute-CM study will be shared at the Annual Congress of the Heart Failure Association of the ESC (Heart Failure 2025), taking place in Belgrade, Serbia on May 17 - 20, 2025.
Neutral
GlobeNewsWire
1 month ago
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025
PALO ALTO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in a fireside chat at the Bank of America Merrill Lynch Global Healthcare Conference 2025 in Las Vegas, NV on Wednesday, May 14 at 2:20 pm PT.
Neutral
Seeking Alpha
1 month ago
BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call Transcript
BridgeBio Pharma, Inc. (NASDAQ:BBIO ) Q1 2025 Earnings Conference Call April 29, 2025 4:30 PM ET Company Participants Chinmay Shukla – Vice President-Strategic Finance Neil Kumar – Chief Executive Officer Matt Outten – Chief Commercial Officer Tom Trimarchi – President and Chief Financial Officer Ananth Sridhar – Chief Operating Officer-BridgeBio Cardiorenal Conference Call Participants Salim Syed – Mizuho Tyler Van Buren – TD Cowen Mani Foroohar – Leerink Partners Cory Kasimov – Evercore Greg Harrison – Scotiabank Paul Choi – Goldman Sachs Anupam Rama – JPMorgan Eliana Merle – UBS Jason Zemansky – Bank of America Operator Good afternoon. I will be your conference operator today.
Charts implemented using Lightweight Charts™